|

ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

RECRUITINGPhase 1/2Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Actively Recruiting
PhasePhase 1/2
SponsorSuzhou Zelgen Biopharmaceuticals Co.,Ltd
Started2025-09-23
Est. completion2027-09
Eligibility
Age18 Years – 70 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07038096

Summary

This study is a randomized, multicenter, Phase Ib/II clinical trial, aimed at evaluating the efficacy and safety of the combination of ZG006 and ZG005 in patients with advanced small cell lung cancer and neuroendocrine carcinoma.

Eligibility

Age: 18 Years – 70 YearsHealthy volunteers accepted
Inclusion Criteria:

* Fully understand the study and voluntarily sign the informed consent form.
* Male or female 18-70 years of age.
* Participants with advanced small cell lung cancer or neuroendocrine carcinoma confirmed by histopathology or cytology.
* Eastern Cooperative Oncology Group (ECOG) 0 to 1.
* Life expectancy \> 3 months.

Exclusion Criteria:

* The investigator believes that the subject has other reasons that make them unsuitable for participation in this study.

Conditions4

CancerLung CancerNeuroendocrine CarcinomaSmall Cell Lung Cancer

Interventions2

ZG005ZG006

Related trials

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.